Effect of Drugs Used in Pharmacotherapy of Type 2 Diabetes on Bone Density and Risk of Bone Fractures

• DOI: 10.20944/preprints202401.1141.v1
• Publication Date: 2024-01-17T04:18:56Z
• Authors: Agnieszka Wikarek; Małgorzata Grabar...; Katarzyna Klimek; Agata Janoska-Gaw...; Magdalena Suchodo...; Michał Holecki
• Keywords: Bone remodeling; Bone fracture

This review summarises the complex relationship between medications used to treat type 2 diabetes, and bone health. T2DM patients face an increased fracture risk despite higher mineral density, thus we analysed impact of key drug classes, including Metformin, Sulphonylureas, SGLT-2 inhibitors, DPP-4 GLP-1 agonists, Thiazolidinediones.
 promising preclinical results, lacks a clear consensus on its role in reducing risk. Sulphonylureas present conflicting data, with potential neutral effects bone. inhibitors seem have transient serum calcium phosphorus, but evidence their association is inconclusive.
 emerge as contributors health, well agonists exhibit positive metabolism, Thiazolidinediones, however, demonstrate adverse impacts bone, inducing loss through mesenchymal stem cell effects. Insulin presents While it has anabolic effect remains inconsistent.
 In conclusion, comprehensive understanding diabetes medications' health crucial. Further research needed formulate guidelines for managing diabetic patients, considering individual profiles, glycemic control medication-related